Innovation and Technology Transfer Office
Networks
The Innovation and Technology Transfer Office is part of the Technology Transfer Office of the Andalusian Public Health System (OTT-SSPA). It is an initiative of the Regional Ministry of Health and Consumer Affairs, dedicated to the protection and commercialization of the technologies developed by the professionals of the Andalusian Public Health System. The OTT-SSPA coordinates the transfer of research results from seven offices distributed in the Research Management Foundations.
ITEMAS is one of the platforms of the Instituto de Salud Carlos III (ISCIII) that supports R&D&I in Biomedicine and Health Sciences, being a reference network that promotes innovation in the health field at national and international level. The Innovation and Technology Transfer Office is part of ITEMAS, collaborating in promoting the transfer of knowledge and technologies from research to clinical practice. Through this collaboration, we strengthen our capabilities in innovation management, facilitating the arrival of new technological solutions to the healthcare system.
The Málaga TechPark is a benchmark for innovation and technology in the region, offering a dynamic environment for collaboration between companies, institutions and research centers. IBIMA Plataforma BIONAND benefits from its cutting-edge ecosystem, facilitating the development and transfer of innovative solutions in the field of biomedicine and nanomedicine. The proximity to the Malaga TechPark allows for the promotion of collaborative projects that accelerate the arrival of new technologies to the market.
The Office in numbers
Active ideas
New patent application
New partnership agreements
Active licenses
License patent families
Technological companies
Projects and innovations in valorization
BRITE-A
BRITE-A addresses obesity through advanced technology (nanoparticle + microRNA), promoting the transformation of white adipose tissue to beige for a more effective and safer treatment.
Principal resercher: Rajaa El Bekay rizky
Research group of IBIMA involved: Endocrinology and Nutrition, Diabetes, and Obesity
I-SOL
I-SOL is a recombinant protein with broad-spectrum antiviral properties designed to provide effective protection against a variety of emerging and re-emerging viral infections. Validated in vitro and in vivo.
Principal resercher: Begoña Oliver Martos
Research group of IBIMA involved: Neuroimmunology and Neuroinflammation
Immunomark
Immunomark seeks to improve cancer treatment by developing a fast and simple test that detects molecules in blood, optimizing therapeutic decisions, increasing treatment efficiency and reducing toxicity and pharmaceutical costs (validated on real patient samples).
Principal resercher: Isabel Barragán Mallofret
Research group of IBIMA involved: Translational Research in Cancer Immunotherapy and Epigenetics
MODY-Tag
Rapid and accurate diagnosis of MODY diabetes, based on functional (microRNA expression) rather than genomic analysis, facilitating better disease management and family screening (cohort >100 patients).
Principal researchers: María Soledad Ruíz de Aldaba and Sara García Serrano
Research group of IBIMA involved: Endocrinology and Nutrition, Diabetes, and Obesity
SAFEPROT Technology
The Safeprot project develops an innovative bioelectric device designed to destroy bacterial biofilms in prosthetic infections, offering an effective solution to reduce the incidence and economic impact of these complications in knee and hip implants.
Principal resercher: Iskandar Tamimi
Research group of IBIMA involved: Innovative Therapies and New Technology in the Musculoskeletal System
Public-private partnership projects
Sistema portable inteligente de monitorización y terapia para trastornos del sueño REM (SMOTTS)
Entities Vectorpipe S. L., Eneso Tecnología de Adaptación S. L., Tecnalia, FIMABIS, UMA
IBIMA Plataforma BIONAND team: Victoria Eugenia Fernández Sánchez, Christiam Antonio Lafuente Bernal, José Carlos López Madrona.
CPP2021-008689 financiado por MCIN/AEI /10.13039/501100011033 y por la Unión Europea-NextGenerationEU/PRTR
Web
Primer kit del mercado para el diagnóstico temprano de la Esclerosis Múltiple en sangre.
Entities ALA Diagnostics S. L., Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, FIMABIS, UMA
IBIMA Plataforma BIONAND team: Begoña Oliver Martos, Victoria Eugenia Fernández Sánchez, Laura Leyva Fernández
CPP2021-008512 financiado por MCIN/AEI /10.13039/501100011033 y por la Unión Europea-NextGenerationEU/PRTR
Development of a photonic point of care device for multiplexed detection of biomarkers, tryptase, IL-6, and PAF in the events of hypersensitivity during oncological or biological agent administration, and anaesthesia (PHOTOCare).
Entities Bioherent S. L., Mecwins S. A., FIMABIS, UMA
IBIMA Plataforma BIONAND team: Inmaculada Doña Díaz, Cristobalina Mayorga Mayorga, María José Torres Jaén
CPP2022-009994 financiado por MICIU/AEI /10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR
MetabPlus: a flexible and efficient multi-IEM, Newborn Screening Program
Entities Reactomix S. L., FIMABIS
IBIMA Plataforma BIONAND team: Rocío Calvo Medina, Raquel Yahyaoui Macías, Gabriel Olverida Fuster, Monsterrat Gonzalo María, Javier Blasco Alonso.
CPP2022-010108 financiado por MCIN/AEI/10.13039/501100011033 y por la Unión Europea-NextGenerationEU/PRTR
Desarrollo y validación de nuevo sistema automático de predicción, diagnóstico y análisis temprano de patologías del tracto urinario inferior, a través de nuevas técnicas de procesado de señal e investigación de IA usando Smartwatch. (SWALU23)
Entities E PROCESS MED, S.L., FIMABIS, Fundación para la Gestión de la Investigación Biomédica de Cádiz, Universidad de Valladolid.
IBIMA Plataforma BIONAND team: Bernardo Herrera Imbroda
CPP2022-010045 financiado por MICIU/AEI /10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR
Partners
